Reconciling the Divergent Findings from Clinical Trials and Observational Studies of Menopausal Hormone Therapy for Prevention of Coronary Heart Disease

Jacques E. Rossouw

doi:10.1055/s-0034-1384625

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2014; 32(06): 426-432
DOI: 10.1055/s-0034-1384625

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Reconciling the Divergent Findings from Clinical Trials and Observational Studies of Menopausal Hormone Therapy for Prevention of Coronary Heart Disease

Jacques E. Rossouw

¹National Heart, Lung, and Blood Institute, Bethesda, Maryland

› Author Affiliations

Abstract

In the Women's Health Initiative (WHI) observational study, current use of estrogen plus progestin therapy (EPT) and estrogen therapy showed an association with reduced risk of coronary heart disease (CHD). However, after taking into account the early increase in risk, the observational study and clinical trial hazard ratios did not differ significantly and showed no benefit for CHD. These findings were confirmed in novel reanalyses for EPT use in the Nurses' Health Study which for the first time included early events and yielded results similar to those of the WHI trial in showing no CHD benefit. The underestimation of CHD risk in observational studies of menopausal hormone therapy appears to lie in their inefficiency at capturing the early increase in risk in current users; by contrast clinical trials are very efficient at capturing early risk. Observational study data mostly reflects long-term use in women who survive the early increase, while trials mainly reflect short-term use. Confounding plays a role, but biologic differences in study populations are unlikely to explain the different risk estimates.

Keywords

estrogen - progestin - coronary heart disease - epidemiology - clinical trials

Full Text

References

References
1 Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 2011; 18 (4) 385-392
2 Grady D, Rubin SM, Petitti DB , et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117 (12) 1016-1037
3 Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72
4 Rossouw JE, Anderson GL, Prentice RL , et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3) 321-333
5 Anderson GL, Limacher M, Assaf AR , et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291 (14) 1701-1712
6 Rossouw JE, Prentice RL, Manson JE , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297 (13) 1465-1477
7 North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19 (3) 257-271
8 Michels KB, Manson JE. Postmenopausal hormone therapy: a reversal of fortune. Circulation 2003; 107 (14) 1830-1833
9 Hulley S, Grady D, Bush T , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (7) 605-613
10 Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006; 15 (1) 35-44
11 Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med 2007; 356 (25) 2639-2641
12 Manson JE, Allison MA, Rossouw JE , et al; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356 (25) 2591-2602
13 Hsia J, Langer RD, Manson JE , et al; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166 (3) 357-365
14 Prentice RL, Langer R, Stefanick ML , et al; Women's Health Initiative Investigators. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162 (5) 404-414
15 Prentice RL, Langer RD, Stefanick ML , et al; Women's Health Initiative Investigators. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006; 163 (7) 589-599
16 Prentice RL, Manson JE, Langer RD , et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170 (1) 12-23
17 Rossouw JE, Prentice RL, LaCroix AZ , et al. Hormone therapy and cardiovascular risk-reply. JAMA 2007; 298: 623-625
18 Hernán MA, Alonso A, Logan R , et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008; 19 (6) 766-779
19 Heiss G, Wallace R, Anderson GL , et al; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299 (9) 1036-1045
20 Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010; 152 (4) 211-217